Zobrazeno 1 - 10
of 2 578
pro vyhledávání: '"Metastatic Castration-resistant Prostate Cancer"'
Publikováno v:
Prostate International, Vol 12, Iss 4, Pp 219-223 (2024)
Background: To compare the efficacy and toxicity of docetaxel treatment regimens in metastatic castration-resistant prostate cancer (mCRPC). Methods: We retrospectively analyzed 162 patients diagnosed with mCRPC who underwent docetaxel chemotherapy b
Externí odkaz:
https://doaj.org/article/355dd609ba144ed7859e3c8307e355c1
Autor:
Shota Torii, Aya Torii-Goto, Tamaki Tanizawa, Takashi Sakakibara, Ryosuke Oguri, Haruka Nagase, Yuri Nakao, Tomoyuki Hirashita, Kuniaki Tanaka, Norio Takimoto, Takahiro Hayashi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background This study aimed to investigate the relationship between low-dose prednisolone (PSL) and the incidence of hypokalaemia at abiraterone acetate (abiraterone) plus PSL combination therapy targeting Japanese patients with metastatic c
Externí odkaz:
https://doaj.org/article/c31ea5e2b6fb4d588635f42f0cf23887
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-4 (2024)
Abstract Background Leptomeningeal metastasis occurs in 5% of patients with prostate cancer and indicates a very poor prognosis. Case presentation A 60-year-old Caucasian male patient diagnosed with metastatic castration-resistant prostate cancer wit
Externí odkaz:
https://doaj.org/article/0737f4b189c2404ea496d69c11e21809
Publikováno v:
Journal of Isotopes, Vol 37, Iss 5, Pp 500-506 (2024)
Prostate specific membrane antigen (PSMA) radioligand therapy (PRLT) has become an important new therapy，especially suitable for the treatment of metastatic castration resistant prostate cancer (mCRPC) which cannot be effectively controlled by conv
Externí odkaz:
https://doaj.org/article/84da18ba7e464b349aa79d9334789610
Autor:
Amir Karimzadeh, Charlotte-Sophie Hecker, Matthias M. Heck, Robert Tauber, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Background The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high
Externí odkaz:
https://doaj.org/article/31e329c31e0949a1906aa3f3aad0cf6d
Autor:
Dheeratama Siripongsatian, Attapon Jantarato, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Peerapon Kiatkittikul, Natphimol Boonkawin, Sukanya Yaset, Sirinsuda Somboon, Chanisa Chotipanich
Publikováno v:
Indian Journal of Radiology and Imaging, Vol 34, Iss 04, Pp 579-587 (2024)
Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying
Externí odkaz:
https://doaj.org/article/cfbdec4d3c9e4966b21c1811fc8c80f4
Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race
Autor:
Bilen MA, Khilfeh I, Rossi C, Muser E, Morrison L, Hilts A, Diaz L, Lefebvre P, Pilon D, George DJ
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 16, Pp 657-674 (2024)
Mehmet Asim Bilen,1 Ibrahim Khilfeh,2 Carmine Rossi,3 Erik Muser,2 Laura Morrison,3 Annalise Hilts,3 Lilian Diaz,3 Patrick Lefebvre,3 Dominic Pilon,3 Daniel J George4 1Department of Hematology and Medical Oncology, Emory University School of Medicine
Externí odkaz:
https://doaj.org/article/21b1cbb5bb98427383e18c20de7c5a9f
Autor:
Mike Wenzel, Carolin Siech, Benedikt Hoeh, Florestan Koll, Clara Humke, Derya Tilki, Thomas Steuber, Markus Graefen, Séverine Banek, Luis A. Kluth, Felix K.H. Chun, Philipp Mandel
Publikováno v:
European Urology Open Science, Vol 66, Iss , Pp 46-54 (2024)
Background and objective: With approval of novel systemic therapies within the past decade for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer, patients may receive several therapy lines. However, the use of thes
Externí odkaz:
https://doaj.org/article/1758ca2edc274ae3ab0b726c095d034f
Autor:
Marisa Cabeza
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/9b6931beb67c4bc79ff93fd8519c7eac
Autor:
I‐Hung Shao, Hsiang‐Shen Wang, Chin‐Hsuan Hsieh, Tsung‐Lin Lee, Ying‐Hsu Chang, Liang‐Kang Huang, Yuan‐Cheng Chu, Hung‐Chen Kan, Po‐Hung Lin, Kai‐Jie Yu, Chun‐Te Wu, Cheng‐Keng Chuang, See‐Tong Pang
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
ABSTRACT Background This study aimed to identify the clinical predictors for the response of patients with mCRPC to ARATs. Materials and Methods We retrospectively collected data on consecutive patients who were diagnosed with mCRPC and underwent ARA
Externí odkaz:
https://doaj.org/article/2e7066fa5e1b493097b1b7e05e3df66d